1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Saved in:
| Title: | 1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). |
|---|---|
| Authors: | Berger, R.1 (AUTHOR), Tolcher, A.W.2 (AUTHOR), Dorff, T.B.3 (AUTHOR), Okubo, S.4 (AUTHOR), Abraham, L.S.4 (AUTHOR), Reilly, R.4 (AUTHOR), Stevenson, C.5 (AUTHOR), Wang, S.4 (AUTHOR), Arnold, J.4 (AUTHOR), Mudd, S.R.4 (AUTHOR), Alaei, S.4 (AUTHOR), Hong, J.4 (AUTHOR), Quinn, D.I.4 (AUTHOR), Saad, F.6 (AUTHOR), Powderly, J.7 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1000-S1001. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
